The role of ETV4 in HCC: How transcription factors can inform immunotherapy combination treatments

J Hepatol. 2023 Jul;79(1):19-21. doi: 10.1016/j.jhep.2023.04.005. Epub 2023 Apr 23.

Authors

Amanda J Craig¹, Maruhen A D Silveira²

Affiliations

¹ Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: Amanda.Craig@nih.gov.
² Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

PMID: 37088313
DOI: 10.1016/j.jhep.2023.04.005

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Hepatocellular* / therapy
DNA-Binding Proteins
Humans
Immunotherapy
Liver Neoplasms* / therapy
Proto-Oncogene Proteins c-ets
Transcription Factors / genetics

Substances

Transcription Factors
DNA-Binding Proteins
ETV4 protein, human
Proto-Oncogene Proteins c-ets